University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital
Search Site | Find a Doctor
Print this page
FONT SIZE
Home > Doctors > Peter R. Carroll

Peter R. Carroll, M.D.

Co-director of Urologic Cancer

Dr. Peter Carroll, co-director of Urologic Cancer at the UCSF Helen Diller Family Comprehensive Cancer Center and chair of Urology at UCSF, is an expert in managing urologic cancers. His areas of interest include innovative methods of urinary tract reconstruction and the impact of cancer detection and treatment on quality of life.

Carroll has authored hundreds of publications, serves as associate editor of the Journal of Urology and plays a key role in other journals. He is principal or co-investigator of many peer-reviewed research grants, including the UCSF Prostate Cancer SPORE and the Molecular Effects of Nutritional Supplements prostate study, both funded by the National Institutes of Health. Carroll holds the Ken and Donna Derr-Chevron Distinguished Professorship. He graduated with honors from Georgetown University School of Medicine and came to UCSF for general surgery training and a urology residency. He completed a fellowship in Urologic Oncology at Memorial-Sloan Kettering Cancer Center before returning to UCSF.

Conditions & Treatments

Clinics

Prostate Cancer Center
1600 Divisadero St., Third Floor
San Francisco, CA 94115
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Prostate Cancer Risk and Prevention Clinic
1600 Divisadero St, Third Floor
San Francisco, CA 94115
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Urologic Surgery and Oncology
1600 Divisadero St., Third Floor
San Francisco, CA 94115
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

More about Peter R. Carroll

Education

Georgetown University 1979

Residencies

UCSF, Urology 1984

Fellowships

Memorial Sloan-Kettering Cancer Center, 0

Selected Research and Publications

  1. Berglund RK, Tangen CM, Powell IJ, Lowe BA, Haas GP, Carroll PR, Canby-Hagino ED, Devere White R, Hemstreet GP, Crawford ED, Thompson IM, Klein EA. Ten-year Follow-up of Neoadjuvant Therapy with Goserelin Acetate and Flutamide Before Radical Prostatectomy for Clinical T3 and T4 Prostate Cancer: Update on Southwest Oncology Group Study 9109. Urology. 2012 Mar; 79(3):633-7.
  2. Aaronson DS, Odisho AY, Hills N, Cress R, Carroll PR, Dudley RA, Cooperberg MR. Proton beam therapy and treatment for localized prostate cancer: if you build it, they will come. Arch Intern Med. 2012 Feb 13; 172(3):280-3.
  3. Arrayeh E, Westphalen AC, Kurhanewicz J, Roach M, Jung AJ, Carroll PR, Coakley FV. Does Local Recurrence of Prostate Cancer After Radiation Therapy Occur at the Site of Primary Tumor? Results of a Longitudinal MRI and MRSI Study. Int J Radiat Oncol Biol Phys. 2012 Feb 11.
  4. Akaza H, Carroll P, Cooperberg MR, Hinotsu S. Fifth Joint Meeting of J-CaP and CaPSURE: Advancing the Global Understanding of Prostate Cancer and Its Management. Jpn J Clin Oncol. 2012 Mar; 42(3):226-36.
  5. Cooperberg MR, Odisho AY, Carroll PR. Outcomes for radical prostatectomy: is it the singer, the song, or both? J Clin Oncol. 2012 Feb 10; 30(5):476-8.
  6. Messing EM, Albertsen P, Andriole GL, Carroll PR, Klein EA. The Society of Urologic Oncology's reply to the US Preventative Services Task Force's recommendation on PSA testing. Urol Oncol. 2012 Jan; 30(1):117-9.
  7. Muglia VF, Westphalen AC, Wang ZJ, Kurhanewicz J, Carroll PR, Coakley FV. Endorectal MRI of prostate cancer: incremental prognostic importance of gross locally advanced disease. AJR Am J Roentgenol. 2011 Dec; 197(6):1369-74.
  8. Reese AC, Fradet V, Whitson JM, Davis CB, Carroll PR. Poor agreement of prostate specific antigen doubling times calculated using ultrasensitive versus standard prostate specific antigen values: important impact on risk assessment. J Urol. 2011 Dec; 186(6):2228-32.
  9. Punnen S, Cooperberg MR, Sadetsky N, Carroll PR. Among potent men post radical prostatectomy, does the need for phosphodiesterase inhibitors have an impact on sexual bother scores? BJU Int. 2012 May; 109(10):1520-4.
  10. Porten SP, Whitson JM, Cowan JE, Perez N, Shinohara K, Carroll PR. Changes in cancer volume in serial biopsies of men on active surveillance for early stage prostate cancer. J Urol. 2011 Nov; 186(5):1825-9.
  11. Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, Hembroff L, Sadetsky N, Saigal CS, Litwin MS, Klein E, Kibel AS, Hamstra DA, Pisters LL, Kuban DA, Kaplan ID, Wood DP, Ciezki J, Dunn RL, Carroll PR, Sanda MG. Prediction of erectile function following treatment for prostate cancer. JAMA. 2011 Sep 21; 306(11):1205-14.
  12. Magbanua MJ, Roy R, Sosa EV, Weinberg V, Federman S, Mattie MD, Hughes-Fulford M, Simko J, Shinohara K, Haqq CM, Carroll PR, Chan JM. Gene expression and biological pathways in tissue of men with prostate cancer in a randomized clinical trial of lycopene and fish oil supplementation. PLoS One. 2011; 6(9):e24004.
  13. Punnen S, Cooperberg MR, Sadetsky N, Carroll PR. Androgen deprivation therapy and cardiovascular risk. J Clin Oncol. 2011 Sep 10; 29(26):3510-6.
  14. Cooperberg MR, Carroll PR, Klotz L. Active surveillance for prostate cancer: progress and promise. J Clin Oncol. 2011 Sep 20; 29(27):3669-76.
  15. Richman EL, Carroll PR, Chan JM. Vegetable and fruit intake after diagnosis and risk of prostate cancer progression. Int J Cancer. 2011 Aug 5.
  16. Cooperberg MR, Mallin K, Kane CJ, Carroll PR. Treatment trends for stage I renal cell carcinoma. J Urol. 2011 Aug; 186(2):394-9.
  17. McKenney JK, Simko J, Bonham M, True LD, Troyer D, Hawley S, Newcomb LF, Fazli L, Kunju LP, Nicolas MM, Vakar-Lopez F, Zhang X, Carroll PR, Brooks JD. The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional study. J Urol. 2011 Aug; 186(2):465-9.
  18. Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer. 2011 Nov 15; 117(22):5039-46.
  19. Porten SP, Whitson JM, Cowan JE, Cooperberg MR, Shinohara K, Perez N, Greene KL, Meng MV, Carroll PR. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol. 2011 Jul 10; 29(20):2795-800.
  20. Richman EL, Kenfield SA, Stampfer MJ, Paciorek A, Carroll PR, Chan JM. Physical activity after diagnosis and risk of prostate cancer progression: data from the cancer of the prostate strategic urologic research endeavor. Cancer Res. 2011 Jun 1; 71(11):3889-95.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions by logging on to UCSF Profiles.

Home • Terms of Use • Site Map • Contact Us       © 2002 - 2012 The Regents of The University of California